Inogen Inc logo

Inogen Inc(INGN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 26 days
PROFIT SINCE LAST BUY
-7.93% ▼
LAST CLOSE
$5.69
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INGN

11/13/2026: INGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Inogen Inc is a medical technology company specializing in portable oxygen concentrators and respiratory health products for homecare settings. The company's core strengths lie in its recognized brand equity and innovative lightweight device engineering, which provide ambulatory freedom to chronic respiratory patients. Its primary investment story centers on an operational turnaround focused on portfolio expansion into adjacent areas like airway clearance and operational streamlining. However, the company faces intense competition from larger medical device conglomerates alongside historical unprofitability and high customer acquisition costs. Inogen suits risk-tolerant growth investors willing to monitor turnaround execution, cost discipline, and new product adoption milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile Inogen operates in an expanding healthcare sub-sector, its historical revenue contraction limits near-term growth appeal.
Momentum investorWeak fitMomentum fit is conditional on a positive sustained upturn signal, given historical share price volatility.
Value investorMixed fitThe stock trades at modest price-to-sales multiples, but unprofitability introduces higher fundamental execution risk.
Dividend investorWeak fitInogen does not pay dividends, rendering it unsuitable for income-seeking investors.
Low-risk investorWeak fitHigh share price volatility and ongoing turnaround execution risks make it unsuitable for risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp swings driven by sentiment shifts, quarterly earnings, and turnaround news.
Valuation riskMediumLow price-to-sales multiples offer some downside buffer, but lack of earnings complicates traditional valuation metrics.
Competition risk (large medical device conglomerates)HighInogen competes against heavily capitalized rivals with broader global scale and distribution power.
Business qualityMediumSpecialized proprietary device technology is offset by historical operating losses and margin pressures.
Dividend incomeLow / noneThe company pays no dividend, offering zero income return.
Execution riskHighSuccessful turnaround hinges on management's ability to control costs and drive scalable commercial growth.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 147.95M USD
Price to earnings Ratio -
1Y Target Price 10.75
Price to earnings Ratio -
1Y Target Price 10.75
Volume (30-day avg) 295.6K shares
Beta 1.49
52 Weeks Range 5.04 - 7.67
Updated Date 11/15/2026
52 Weeks Range 5.04 - 7.67
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.21

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -53.8%
Avg. Invested days 27
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INGN receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
INGN has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, strong earnings growth (+36.6%) is partially offset by weak cash generation (FCF margin -6.2%), moderate revenue growth (+3.9%), weak profitability (net margin -6.5%).

Financial Health Rating

★★★★★
INGN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 45.1%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is INGN's strongest growth driver at +36.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+3.9%, moderate) and free-cash-flow growth (-93.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 81.7% and approximately 86.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 13.94% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 6.73%
Acadian Asset Management LLC 4.22%
Armistice Capital, LLC 4.22%
Vanguard Capital Management, LLC 3.99%
Ameriprise Financial Inc 3.78%

Unit Economics (Per $1K Revenue)

★★★★★
INGN generates approximately $476 of gross profit, $-87 of operating income, and $-62 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.70%

Quantitative Style Profile

★★★★★
INGN has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Portable Oxygen Concentrators (POC)Sale and rental of flagship ambulatory devices such as the Inogen One G3, G4, and G5 systems.This is the core revenue engine where patients pay for lifestyle-oriented mobile oxygen devices.
Domestic and International B2B / DTC ChannelsDirect sales to consumers and wholesale transactions through home medical equipment providers and international distributors.Diversified distribution helps reach patients globally, balancing direct marketing costs with wholesale volume.
Home Respiratory and Adjacent ProductsStationary concentrators, consumables, and airway clearance products like Simeox.Newer product categories provide secondary avenues for revenue diversification beyond standard POCs.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 65.91M
Price to Sales(TTM) 0.42
Enterprise Value 65.91M
Price to Sales(TTM) 0.42
Enterprise Value to Revenue 0.19
Enterprise Value to EBITDA -17.6
Shares Outstanding 26.00M
Shares Floating 22.59M
Shares Outstanding 26.00M
Shares Floating 22.59M
Percent Insiders 13.94
Percent Institutions 81.68

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.